NSE: GLENMARK · 23 October 2026
- Glenmark Pharmaceuticals shares fell 3.55% today, settling at ₹2120.40 after moving within an intraday range of ₹2101.90 and ₹2203.80.
- Glenmark Therapeutics Inc., USA announced the launch of Adapalene Gel USP, 0.1% (OTC) in new pump packs. The product is comparable to the active ingredient of Differin Gel, a market that recorded annual sales of approximately $45.8 million based on Nielsen syndicated data for the 52-week period ending September 5, 2026. Management noted the new dispensing format enhances consumer experience while strengthening its U.S. dermatology portfolio.
- Trading volume was 0.73 times the 20-day average daily volume.
Why is Glenmark Pharmaceuticals share price falling on 23 October 2026?
Glenmark Pharmaceuticals shares fell 3.55% today, settling at ₹2120.40 after moving within an intraday range of ₹2101.90 and ₹2203.80.
The broader market witnessed selling pressure, with the Nifty declining 0.90% while the sectoral benchmark Nifty Pharma dropped 1.04%. Glenmark's negative return for the session aligned with the broader downturn observed across healthcare equities, extending its recent weakness that includes a 5.78% decline over the past 5 trading days and a 14.33% pullback over the past 20 trading days.
While no single company-specific trading catalyst was announced for the session, recent corporate developments provide operational context for the stock. Earlier in October 2026, Glenmark Therapeutics Inc. launched Adapalene Gel USP, 0.1% in new pump packs in the US, tapping a market with annual sales of approximately $45.8 million based on Nielsen data for the period ending September 5, 2026. This followed the receipt of an Establishment Inspection Report with VAI classification from the U.S. FDA for its Goa facility in September 2026.
4.67 lakh shares traded by 23 October 2026 · 03:00 PM IST. This compares with a 20-day average daily volume of 6.44 lakh shares (0.73 times). The five-day average daily volume was 5.23 lakh shares. Separately, the NSE report for 22 October 2026 showed 3.19 lakh shares delivered, representing 55.29% of that day’s traded volume. The same report recorded 36,963 trades.
The decline in Glenmark shares aligns with broader weakness across pharmaceutical equities and general market sentiment, accompanied by subdued trading volume below its 20-day average. Recent positive product launches and regulatory updates provide fundamental context but did not prevent profit-taking or sector-aligned selling pressure.
Latest Company Developments
Glenmark Therapeutics Inc., USA announced the launch of Adapalene Gel USP, 0.1% (OTC) in new pump packs. The product is comparable to the active ingredient of Differin Gel, a market that recorded annual sales of approximately $45.8 million based on Nielsen syndicated data for the 52-week period ending September 5, 2026. Management noted the new dispensing format enhances consumer experience while strengthening its U.S. dermatology portfolio.
Expands the company's over-the-counter dermatology footprint in the United States within an established multi-million dollar product category.
Glenmark Pharmaceuticals received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration for its formulations manufacturing facility in Goa, India. The inspection, conducted between June 22 and June 30, 2026, concluded with a Voluntary Action Indicated (VAI) classification.
formal closure of the inspection status removes regulatory uncertainty surrounding a key manufacturing site catering to regulated markets.
Glenmark Specialty S.A. announced the commercial launch of Ryaltris Nasal Spray in Brazil following regulatory approval from ANVISA. The therapy targets moderate to severe symptoms of allergic rhinitis in adults and adolescents aged 12 and older, introducing the country's first olopatadine-containing intranasal combination therapy.
Strengthens the company's innovative respiratory portfolio in Latin America's largest healthcare market, where allergic rhinitis affects an estimated 20% to 30% of the population.
a press release dated October 06, 2026, titled "Glenmark Therapeutics Inc., USA launches Pump Packs for Adapalene Gel USP, 0.1% (OTC)".
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 15.61% on 30 September 2026. This compares with 16.76% on 30 June 2026, a change of -1.15 percentage points.
The filing reported 38 MF/UTI holders.
Research & Brokerage Views
Recommended as a stock pick by analyst Chandan Taparia in NDTV Profit coverage.
Maintained a hold rating with a price target of Rs 2100.
What to Watch Next
- Upcoming financial results and operational updates for the quarter ending September 30, 2026
- Execution and market uptake of the newly launched Adapalene Gel pump packs in the US
- Progress on commercial expansion of Ryaltris in international markets including Brazil
- Sustained cash market delivery participation relative to the 55.29% delivery rate recorded on October 22, 2026
Other Dated Coverage
- Glenmark Pharmaceuticals in Focus After US Adapalene Gel Launch | 8 October 2026 — 8 October 2026
- Glenmark Pharmaceuticals Share Price Today: Why GLENMARK Is Falling 1.24% | 7 October 2026 — 7 October 2026
- Why Glenmark Pharmaceuticals Shares Are Up 0.70% Today | 6 October 2026 — 6 October 2026
More Glenmark Pharmaceuticals news and dated analysis →
Frequently Asked Questions
What is the latest Glenmark Pharmaceuticals company news?
Glenmark Therapeutics Inc., USA announced the launch of Adapalene Gel USP, 0.1% (OTC) in new pump packs. The product is comparable to the active ingredient of Differin Gel, a market that recorded annual sales of approximately $45.8 million based on Nielsen syndicated data for the 52-week period ending September 5, 2026. Management noted the new dispensing format enhances consumer experience while strengthening its U.S. dermatology portfolio.
How strong was Glenmark Pharmaceuticals’s trading volume?
4.67 lakh shares traded, 0.73 times the 20-day average daily volume. The price and volume data are dated 23 October 2026 · 03:00 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.